CADL Candel Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1841387 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-335.6%
TTM EPS YoY-173.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-93.6%
ROA-65.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets37.7%
Debt / equity0.00x
Current ratio7.57x
Interest coverage-13.30x
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-19.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $30.50M | $19.31M |
| SG&A expense | $17.77M | $14.06M |
| Operating income | -$48.27M | -$33.37M |
| Interest expense | $2.12M | $2.09M |
| Pretax income | -$38.18M | -$55.18M |
| Income tax | $0 | $0 |
| Net income | -$38.18M | -$55.18M |
| EBITDA | -$47.42M | -$32.38M |
| EPS (basic) | -0.72 | -1.74 |
| EPS (diluted) | -0.72 | -1.74 |
| Weighted avg. shares (diluted) | 52.96M | 31.68M |
| Balance sheet | ||
| Cash & equivalents | $119.73M | $102.92M |
| Current assets | $121.39M | $103.80M |
| PP&E, net | $1.64M | $2.19M |
| Total assets | $125.19M | $106.87M |
| Current liabilities | $9.00M | $37.53M |
| Short-term debt | $0 | $9.89M |
| Long-term debt | — | $1.73M |
| Total debt | — | $11.63M |
| Total liabilities | $73.27M | $40.54M |
| Shareholders' equity | $51.92M | $66.33M |
| Net debt | — | -$91.29M |
| Shares outstanding | 54.90M | 46.81M |
| Cash flow statement | ||
| Operating cash flow | -$38.31M | -$27.02M |
| Capital expenditure | $587,000 | $16,000 |
| Free cash flow | -$38.90M | -$27.04M |
| Investing cash flow | -$560,000 | -$16,000 |
| Financing cash flow | $56.10M | $94.28M |
| Depreciation & amortization | $845,000 | $990,000 |
| Stock-based compensation | $3.82M | $5.31M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.